← All organizations

Eisai

For profitContributed to NMEWebsite ↗

Also known as: Clinical Research Center, Eisai, Co., Ltd | Drug Fostering and evolution Coodination Department, Corporate Regulattory Compliance, Safety and Quality Assurance Headquaters, Eisai Co., Ltd., Japan | Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd. | Drug Fostering and Evolution Coordination Department, Corporate Regulatory Compliance, Safety and Quality Assurance Headquarters, Eisai Co., Ltd. | Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd. | Drug Fostering and Evolution Cordination Department, Eisai Co., Ltd. | Eisai Asia Regional Services Ltd. | Eisai China Inc. | Eisai Co., Ltd. | Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center | Eisai Co., Ltd - Development Clinical Research Dept., Clinical Research Center | Eisai Company Lmited | Eisai Farmaceutica, S.A. | EISAI Farmaceutica S.A. Head of Medical Department | Eisai France | Eisai Global Clinical Development | Eisai Global Study Director | Eisai GmbH | Eisai GmbH, Frankfurt, Germany | Eisai Inc. | EISAI INC | Eisai, Incorporated | Eisai Korea | Eisai Korea Inc. | Eisai Limited | Eisai Limted | EISAI MEDCL RES | Eisai Medical Research (formerly MGI Pharma Inc.) | Eisai Medical Services | Eisai/Morphotek | Eisai Pharmaceuticals India Private limited | Eisai Pharmaceuticals India Pvt. Ltd | Eisai Research Institute | Eisai Taiwan | Frontier Product Creation Unit, Eisai Product Creation Systems | General Manager - Medical and Regulatory Affairs, Eisai Pharmaceuticals India Private Limited | General Manager Medical & Regulatory Affairs, Eisai Pharmaceuticals India Private Limited, Mumbai, MS, India | H3 Biomedicine Inc. | JAC PCU Eisai Co., Ltd. | JAC PCU. EPCS, Eisai Co., Ltd. | Japan/Asia Clinical Research Product Creation Unit | Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd. | Japan/Asia Clinical Research Product Creation Unit, Japan Clinical Development, Japan Clinical Development Section | Japan Clinical Pharmacology, Eisai Co., Ltd. | KAN Clinical Development Section, JAPAN/ASIA Clinical Research Product Creation Unit, Eisai Product Creation System | Medical Affairs Department , Eisai Taiwan Inc. | Medical Affairs, Eisai, Inc | Medical Department, Eisai Korea Inc. | Neuroscience Cliical Development Section, Japan /Asia Clinical Research PCU | Neuroscience Clinical Development Section. JAC PCU | Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd. | Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd. | Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd. | Neurosciences Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System. | New Drug Development Department, Eisai Company Limited | New Product Development, Clinical Research Center, Eisai Co., Ltd. | Oncology Clinical Development Section. JAC PCU. Eisai Co., Ltd. | Oncology Clinical Development Section. JAC PCU., Eisai, Co., Ltd | Oncology Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System | Post -marketing Clinical Research Department, Clinical Research Center - Eisai Company Limited

Highest phase reached

Phase 4

First clinical trial

Jun 1, 1995

First marketed drug

Dec 26, 1990

First NDA

Nov 25, 1996

Last known activity

Dec 31, 2025

Acquired by Sarepta Therapeutics on Jan 1, 2014

Timeline

1940s

  1. Jan 1, 1944

    Sakuragaoka Laboratory Co, Ltd— Acquired

1950s

  1. Jan 1, 1955

    Eisai— Founded

  2. Jan 1, 1955

    Nihon Eisai— Acquired

1990s

  1. Feb 5, 1999

    denileukin diftitox— NDA Secondary Org

2000s

  1. Apr 19, 2007

    Morphotek— Acquired

  2. Jan 28, 2008

    MGI Pharma— Acquired

2010s

  1. Jan 6, 2010

    AkaRx— Acquired

  2. Jan 1, 2014

    Sarepta Therapeutics— Acquired By

  3. Dec 4, 2015

    Liaoning TianYi Biological Pharmaceutical Co., Ltd.— Acquired

  4. Dec 20, 2019

    lemborexant— Marketing Organization

  5. Dec 20, 2019

    lemborexant— NDA Organization

Drugs by trial phase (216 distinct, 731 trials)

Indications

Studied for

Marketed drugs (14)

Subsidiaries (6 direct, 8 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Saitama, JP Jan 1, 1955
First NDA
Nov 25, 1996
Last known activity
Dec 31, 2025

Designations held

  • Orphan drug
  • Priority review